



## **ResMed Launches Narval™ CC Mandibular Repositioning Device in the US**

*Expands Current Therapy Range and Patient Reach to “Treat the Untreated”*

**SAN DIEGO, CA, June 13, 2012** – ResMed Inc. (NYSE:RMD), a leading developer, manufacturer and distributor of sleep and respiratory medical equipment, announced the US launch of Narval™ CC, its state-of-the-art mandibular repositioning device. The company unveiled the product at last week’s American Academy of Dental Sleep Medicine annual meeting. Building on years of market leadership in France, its country of origin, Narval CC is an innovative, effective, world-class device that offers an alternative solution to patients for snoring and obstructive sleep apnea.

ResMed’s introduction of Narval CC follows its acquisition of the France-based Laboratoires Narval. With the acquisition, ResMed added an additional therapy method to complement its comprehensive positive airway pressure (PAP) solutions, providing a broader offering for snoring and obstructive sleep apnea sufferers.

“Obstructive sleep apnea is a severe disease which, left untreated, can have significant long-term impacts on serious conditions including heart disease, type 2 diabetes, obesity, chronic obstructive pulmonary disease, and, as very recent research has shown, cancer,” stated Michael Farrell, president, ResMed Americas. “The gold-standard therapy for obstructive sleep apnea is PAP therapy. However, we know that today some patients either refuse PAP treatment or fail to comply. Narval CC provides an effective alternative for those untreated patients. With the release of Narval CC, ResMed is now the only PAP company with a customized solution for noncompliant patients or patients who refuse PAP treatment, giving our customers and patients another choice in their treatment.”

The Narval CC provides clinically proven treatment for snoring and OSA.<sup>1-3</sup> The cornerstone of the design is how it maintains the lower jaw in a forward position with a patented optimized retention of the mandible. This allows natural movement of the jaw, increasing patient comfort, and resulting in superior compliance and efficacy. Each device is custom-made to suit the complex dental anatomy of individual patients using a nimble and scalable computer-aided design and computer-aided manufacturing (CAD/CAM) process.

“Narval CC’s proprietary design combined with CAD/CAM technology offers one of the lightest solutions on the market. Precision-enabled digital dentistry has arrived in the mandibular repositioning device market,” said Kristie Burns, general manager, dental sleep, ResMed. “With Narval CC, we finally have a way to reach a previously untreatable patient group with a solution to help them achieve a healthy night’s sleep.”

### **About ResMed**

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and

healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit [www.resmed.com](http://www.resmed.com).

1 Vecchierini M et al. Efficacy and compliance of mandibular repositioning device in obstructive sleep apnea syndrome under a patient-driven protocol of care. *Sleep Med* 2008;9(7):762–769

2 Dookun R. 18 month assessment of 54 patients referred for treatment of anti-social snoring (AHI  $\leq$  30/hr) with a custom Mandibular Repositioning Device (MRD). Paper presented at the World Association of Sleep Medicine & Canadian Sleep Society Congress 2011

3 Geraads et al. First intention management of obstructive sleep apnea syndrome (OSAS) by custom-made mandibular advancement device: the medium-term results. Prospective study by the General Hospital Pneumologists College (CPHG). *Rev Pneumol Clin* 2010;66(5):284–292

For more information, please contact:

**IR Contact:** Constance Bienfait  
858 836-5971

**PR Contact:** Kristie Burns  
858 836-6115